Neuromuscular disorders are currently diagnosed by infrequent and often non-quantitative clinical observations of motion. Drug discovery and treatment protocols rely on the subjective response to “How are you doing now?” – the opposite of precision.
The Atlas5D Echo is a sensor that quantifies motion, with high precision in the home without using video or necessitating that anything be worn. With two granted patents, it uses machine learning for motion biomarker discovery to precisely measure disease progression.
While already receiving revenues from trials with two pharmaceutical companies, the GreyBird investment will allow Atlas5D to fully develop their technology and begin to gather the world’s largest precision motion biomarker database for multiple diseases.